The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; Dendreon; Dendreon; Dendreon; Dendreon; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Seagen; Seagen; Seagen; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; Dendreon; Dendreon; Dendreon; Dendreon; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Pfizer; Pfizer; Pfizer; Pfizer
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Dendreon; Dendreon; Dendreon; Dendreon; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen
 
Xinhua Zhu
No Relationships to Disclose
 
Paul Monk
Honoraria - Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis
Consulting or Advisory Role - Dendreon; Dendreon; Dendreon; Dendreon; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Pfizer/NCCN; Pfizer/NCCN; Pfizer/NCCN; Pfizer/NCCN; Sanofi; Sanofi; Sanofi; Sanofi
Speakers' Bureau - Janssen; Janssen; Janssen; Janssen
 
Robert J. Jones
Honoraria - Advanced Accelerator Applications/Novartis; Advanced Accelerator Applications/Novartis; Advanced Accelerator Applications/Novartis; Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Elsevier; Elsevier; Elsevier; Elsevier; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; WebMD; WebMD; WebMD; WebMD
Consulting or Advisory Role - Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; Bristol-Myers Squibb/Celgene; IPSEN; IPSEN; IPSEN; IPSEN; Janssen; Janssen; Janssen; Janssen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; MSD; MSD; MSD; MSD
 
Mark David Linch
Consulting or Advisory Role - ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; ADC Therapeutics; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; BioNTech; BioNTech; BioNTech; BioNTech; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst)
Travel, Accommodations, Expenses - bristol myers squibb; bristol myers squibb; bristol myers squibb; bristol myers squibb; Janssen; Janssen; Janssen; Janssen; MSD; MSD; MSD; MSD
 
Dan Costin
No Relationships to Disclose
 
Johann S. De Bono
Employment - Institute of Cancer Research; Institute of Cancer Research; Institute of Cancer Research; Institute of Cancer Research
Honoraria - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BioExcel; BioExcel; BioExcel; BioExcel; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Celgene; Celgene; Celgene; Celgene; CellCentric; CellCentric; CellCentric; CellCentric; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genmab; Genmab; Genmab; Genmab; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Harpoon; Harpoon; Harpoon; Harpoon; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Medivation; Medivation; Medivation; Medivation; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Orion; Orion; Orion; Orion; Pfizer; Pfizer; Pfizer; Pfizer; Qiagen; Qiagen; Qiagen; Qiagen; Sanofi; Sanofi; Sanofi; Sanofi; Sierra Oncology; Sierra Oncology; Sierra Oncology; Sierra Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Terumo; Terumo; Terumo; Terumo; Vertex; Vertex; Vertex; Vertex
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BioXCel therapeutics; BioXCel therapeutics; BioXCel therapeutics; BioXCel therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; CellCentric; CellCentric; CellCentric; CellCentric; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genmab; Genmab; Genmab; Genmab; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Harpoon; Harpoon; Harpoon; Harpoon; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Orion; Orion; Orion; Orion; Pfizer; Pfizer; Pfizer; Pfizer; Qiagen; Qiagen; Qiagen; Qiagen; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi Aventis GmbH; Sanofi Aventis GmbH; Sanofi Aventis GmbH; Sanofi Aventis GmbH; Sierra Oncology; Sierra Oncology; Sierra Oncology; Sierra Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Terumo; Terumo; Terumo; Terumo; Vertex; Vertex; Vertex; Vertex
Research Funding - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; CellCentric; CellCentric; CellCentric; CellCentric; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genmab; Genmab; Genmab; Genmab; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Harpoon; Harpoon; Harpoon; Harpoon; Janssen; Janssen; Janssen; Janssen; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Orion; Orion; Orion; Orion; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Sanofi Aventis GmbH; Sanofi Aventis GmbH; Sanofi Aventis GmbH; Sanofi Aventis GmbH; Sierra Oncology; Sierra Oncology; Sierra Oncology; Sierra Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Vertex; Vertex; Vertex; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); Abiraterone Rewards to Inventors (Inst); Abiraterone Rewards to Inventors (Inst); Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); CHK1 inhibitor (Inst); CHK1 inhibitor (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); PARP inhibitors and DNA repair defects (Inst); PARP inhibitors and DNA repair defects (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst); Targeting of IL23 in prostate cancer (Inst); Targeting of IL23 in prostate cancer (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BioXCel therapeutics; BioXCel therapeutics; BioXCel therapeutics; BioXCel therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Cellcentric; Cellcentric; Cellcentric; Cellcentric; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genmab; Genmab; Genmab; Genmab; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Harpoon; Harpoon; Harpoon; Harpoon; Janssen; Janssen; Janssen; Janssen; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Menarini Silicon Biosystems; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Orion; Orion; Orion; Orion; Pfizer; Pfizer; Pfizer; Pfizer; Qiagen; Qiagen; Qiagen; Qiagen; Qiagen; Qiagen; Qiagen; Qiagen; Sanofi; Sanofi; Sanofi; Sanofi; Sierra Oncology; Sierra Oncology; Sierra Oncology; Sierra Oncology; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Terumo; Terumo; Terumo; Terumo; Vertex; Vertex; Vertex; Vertex
 
Lawrence Ivan Karsh
Stock and Other Ownership Interests - Swan Valley Medical (I); Swan Valley Medical (I); Swan Valley Medical (I); Swan Valley Medical (I)
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Dendreon; Dendreon; Dendreon; Dendreon; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Roche; Bristol-Myers Squibb/Roche; Bristol-Myers Squibb/Roche; Bristol-Myers Squibb/Roche; Dendreon; Dendreon; Dendreon; Dendreon; Ferring; Ferring; Ferring; Ferring; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; Pfizer; Pfizer; Pfizer; Pfizer
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Dendreon; Dendreon; Dendreon; Dendreon; Janssen; Janssen; Janssen; Janssen; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bioxell Pharma (Inst); Bioxell Pharma (Inst); Bioxell Pharma (Inst); Bioxell Pharma (Inst); Bristol-Myers Squibb/Sanofi (Inst); Bristol-Myers Squibb/Sanofi (Inst); Bristol-Myers Squibb/Sanofi (Inst); Bristol-Myers Squibb/Sanofi (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Exact Sciences (Inst); Exact Sciences (Inst); Exact Sciences (Inst); Exact Sciences (Inst); Ferring (Inst); Ferring (Inst); Ferring (Inst); Ferring (Inst); FKD Therapies (Inst); FKD Therapies (Inst); FKD Therapies (Inst); FKD Therapies (Inst); Genomic Health (Inst); Genomic Health (Inst); Genomic Health (Inst); Genomic Health (Inst); Hinova Pharmaceuticals (Inst); Hinova Pharmaceuticals (Inst); Hinova Pharmaceuticals (Inst); Hinova Pharmaceuticals (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); KDx Diagnostics (Inst); KDx Diagnostics (Inst); KDx Diagnostics (Inst); KDx Diagnostics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Myovant Sciences (Inst); Myovant Sciences (Inst); Myovant Sciences (Inst); Myovant Sciences (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Tavanta Therapeutics (Inst); Tavanta Therapeutics (Inst); Tavanta Therapeutics (Inst); Tavanta Therapeutics (Inst); Vaxiion (Inst); Vaxiion (Inst); Vaxiion (Inst); Vaxiion (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; dendreon; dendreon; dendreon; dendreon; Janssen; Janssen; Janssen; Janssen; Pfizer; Pfizer; Pfizer; Pfizer
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi
 
Pascal Borderies
Employment - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
Travel, Accommodations, Expenses - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
 
Rashmi Majali Deshpande
Employment - Bioxcel Therapeutics; Bioxcel Therapeutics; Bioxcel Therapeutics; Bioxcel Therapeutics
Stock and Other Ownership Interests - BioXCel therapeutics; BioXCel therapeutics; BioXCel therapeutics; BioXCel therapeutics
 
Amir Hafeez
Employment - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
Travel, Accommodations, Expenses - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
 
Vincent J. O'Neill
Employment - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
Travel, Accommodations, Expenses - BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics; BioXcel Therapeutics
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma; Abbvie; Abbvie; Abbvie; Abbvie; AIkido Pharma; AIkido Pharma; AIkido Pharma; AIkido Pharma; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Dendreon; Dendreon; Dendreon; Dendreon; Endocyte; Endocyte; Endocyte; Endocyte; Genentech; Genentech; Genentech; Genentech; Genomic Health; Genomic Health; Genomic Health; Genomic Health; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Medivation; Medivation; Medivation; Medivation; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; POINT Biopharma; POINT Biopharma; POINT Biopharma; POINT Biopharma; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Tolmar; Tolmar; Tolmar; Tolmar
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Sanofi; Sanofi; Sanofi; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics